Orhub's Story Proves the Power of a Winning Culture
Rhea-AI Summary
ORHub has made strides in improving hospital relationships with biotech firms, focusing on enhancing surgical experiences. The company recently completed its FutureORTM software, which aims to streamline operations in hospital operating rooms. Additionally, ORHub is pursuing an acquisition of PUR Biologics, known for its innovative bone regeneration and pain management products. Plans for rebranding and strengthening public market communications are underway, with a vision to develop a Digital Health and Regenerative Therapeutic division. ORHub's leadership expresses optimism about future growth and shareholder value.
Positive
- Completion of FutureORTM software aimed at operational efficiency in hospitals.
- Pursuing acquisition of PUR Biologics, expanding product portfolio and addressing chronic pain.
- Ongoing efforts to reduce debt and enhance public communications.
Negative
- None.
News Market Reaction – ORHB
In the trading session that priced this news, ORHB declined 11.70%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
IRVINE, CA / ACCESSWIRE / March 14, 2022 / An Important message from the Chairman & CEO
Dear Shareholders,
It is an exciting time for ORHub. Our vision for the Company began in the operating room where we identified opportunities to improve the business relationship shared between hospital and medical device / biotech companies that ultimately impact a patient's surgical experience. Our mindset on Changing Business for GoodTM will not waiver and will continue to guide our business design and strategy, while remaining focused on helping deliver sustainable healthcare and future innovation.
ORHub has made significant progress on all fronts: removing distractions, continuing relevant filings, reducing debt, and ongoing preparation for an audit. We have made a significant investment to develop and recently completed the long-awaited FutureORTM software, designed to deliver efficiency for hospital operating rooms and participating biological & medical device vendors. FutureORTM enables new digital processes to increase payment speed with these manufacturers, while controlling cost and accuracy for the hospitals. ORHub is in continued discussions to acquire, merge, or partner with strategic businesses that fit our vision in healthcare technologies. Our goal with these transactions, is to achieve fast and profitable growth using current product and opportunities with highly scalable potential with our market channels and leverage.
ORHub has entered a LOI and is pursuing an acquisition of PUR Biologics, an ortho-biologic company. PUR brings a product portfolio for bone regeneration and a patent portfolio including interests in regenerating mature hyaline cartilage, skin health & aesthetics. PUR's research explores novel changes to how we address chronic pain, osteoarthritis, and a potentially significant neurological application.
Along with our new website, which is being prepared by branding professionals, ORHub is reestablishing its social media presence, and will steadily increase public market and investor communications.
As we shape the Company's future operations to include a Digital Health and Regenerative Therapeutic division, we anticipate a "new corporate name" will soon be launched to support our significant progress and to best represent our evolving Company.
We are excited about the future of ORHub and look forward to increasing your share value. Thank you for your support.
Sincerely,
CJ Wiggins
Chairman & CEO
SOURCE: ORHUB, Inc.
View source version on accesswire.com:
https://www.accesswire.com/692869/Orhubs-Story-Proves-the-Power-of-a-Winning-Culture